The study revolves around the innovative use of ferritin, a naturally occurring protein, as a means to recover critical metals from electronic waste. Ferritin is a remarkable protein that serves as a nanocage, allowing it to encapsulate and subsequently isolate specific ions from complex mixtures. This method provides a significant advantage over conventional recycling techniques that often lead to significant material losses and chemical waste. By employing ferritin as a biomining tool, researchers aim to change the landscape of material recovery and recycling.

Meng Wang, an assistant professor at the Swanson School of Engineering at the University of Pittsburgh, has been at the forefront of this research. With a focus on environmental remediation and sustainability, Wang’s team has pioneered methods that leverage the unique properties of ferritin to sequester valuable metals from liquid solutions.

In 2019, the United States generated approximately 7 million tons of electronic waste, with a mere 15% of the critical materials being recovered. This figure falls below the global average of 17%, underscoring a pressing need for improved recycling methods. Notably, the unrecovered metals represent a staggering economic loss of about $7 billion. Wang believes that the efficient recycling of these critical materials could significantly bolster the supply chain, providing essential resources for numerous industries that rely on these metals.

Wang’s research team has demonstrated that ferritin is capable of selectively binding to metal ions. In various experiments, the protein showed an exceptional affinity for cobalt ions, achieving concentrations within the ferritin nanocages that were thousands of times greater than those remaining in the solution. This remarkable selectivity enables the creation of localized concentrations of metal ions, facilitating their precipitation and subsequent recovery. By concentrating valuable resources, the process not only maximizes recovery rates but also minimizes the environmental impact typically associated with metal recovery.

The team’s approach to utilizing ferritin also showcases its versatility. While haloferroidions are extracted from lithium-ion battery components, ferritin is adept at differentiating between various metals within the mixture. In addition to its strong affinity for cobalt, Wang’s findings showed that ferritin also holds a significant affinity for nickel ions; however, its attraction to lithium ions was minimal. This selectivity allows for the possibility of separating these metals more efficiently during the recycling process, leading to purer outputs.

Wang envisions a future where recycling can occur under benign conditions, negating the need for harsh solvents and chemicals commonly employed in traditional extraction processes. Current methods of solvent extraction can have a damaging effect on the environment, not to mention the complexities involved in the safe disposal of hazardous waste. An eco-friendly process such as the one designed around ferritin has numerous benefits, including reducing energy consumption and minimizing chemical byproducts.

The research group is now focused on unraveling the molecular mechanisms that underpin the selective affinity of ferritin for specific metals. While it’s understood that the protein’s net negative charge plays a pivotal role in this selectivity, the team is keen to explore why cobalt and nickel exhibit different binding behaviors despite both being positively charged. This aspect of their research promises to unlock new avenues for engineering ferritin-derived nanocages that can be tailored to selectively recover individual metals more effectively.

To capitalize on these findings, Wang imagines a system that could incorporate multiple variations of ferritin, each designed for specific metal recovery tasks. This modular approach would involve using distinct ferritin types within separate tanks—all working together in a cohesive recycling strategy. Each tank would efficiently recover different metals, therefore streamlining the process and ensuring that vital materials are not wasted during recycling.

The trajectory of this research indicates that we are on the cusp of a new frontier in material recovery that could fundamentally alter how industries deal with electronic waste. As critical metals diminish, the implementation of such innovative methodologies becomes not just advantageous but essential for sustainable development. The implications for both environmental health and economic stability are vast, paving the way for a future where e-waste can be transformed from a pressing burden into a rich source of reusable materials.

In conclusion, the team led by Meng Wang at the University of Pittsburgh is making significant strides toward innovating the recycling industry. Ferritin offers a promising alternative to conventional methods, aligning the recovery of critical metals with more environmentally friendly practices. As the demand for efficient recycling of electronic waste intensifies, this research represents a hopeful and practical step toward harnessing the potential of biotechnology in sustainable resource management.

Subject of Research: Recovery of critical metals from electronic waste using ferritin protein nanocages
Article Title: Ferritin Protein Nanocages for Selective Separation and Recovery of Critical Metals
News Publication Date: 15-Apr-2025
Web References: http://dx.doi.org/10.1021/acs.estlett.5c00181
References: Environmental Science & Technology Letters
Image Credits: Paul Kovach/University of Pittsburgh

Keywords

Metal recycling, Separation methods, Sustainability

The foundation of this revolution rests upon a remarkable insight: when provided with the proper environment, cells possess an innate ability to organize themselves and function effectively. This understanding shapes the development of scaffolds that closely resemble natural biological structures, thereby supplying cells with essential cues for growth and interaction. These specially designed scaffolds are critical for enabling engineers to create synthetic tissues that closely mimic the functionality of real organs.

Shiwarski’s introduction of collagen-based, high-resolution scaffolds—dubbed CHIPS—marks a significant leap forward in tissue engineering. These unique structures are internally perfusable and can seamlessly integrate with a vascular organ-on-a-chip system to mimic the dynamic cellular environment found within human tissues. Collaborating with Adam Feinberg, a distinguished professor at Carnegie Mellon University, Shiwarski’s team has shared their findings in a notable publication featured on the cover of the prestigious journal Science Advances. The article highlights innovative strategies for utilizing 3D bioprinting to forge fully biologic tissue systems.

A pivotal aspect of the research involves leveraging additive manufacturing techniques to unlock new potentials for generating functional replacement tissues. In addition to creating tissues, these models offer researchers valuable insights into various diseases, including diabetes and hypertension. The current methodology adopted for studying these conditions—in vitro microfluidic modeling—utilizes minute channels embedded within microchips to simulate blood vessel behaviors. Notably, these microfluidic platforms have traditionally relied on silicone materials, which, despite being useful, restrict the potential for biological interactions due to their synthetic nature.

Shiwarski emphasizes the transformative potential of their collagen-based scaffolds, asserting that they allow cells to thrive in an environment that closely replicates their natural conditions. Unlike traditional microfluidic devices, which typically uphold rigid designs, these bioengineered scaffolds are composed entirely of collagen. This fundamental difference enables cells not only to interact with the structure but also to grow and self-organize into functional tissues, effectively revolutionizing the landscape of tissue engineering.

This newfound capability was demonstrated when the team successfully combined collagen scaffolds with vascular cells and pancreatic cells. The result was a striking mimicry of natural physiological functions, exemplified by insulin secretion in response to glucose levels. This ability to replicate vital biological processes propels forward the prospect of developing organs capable of addressing insulin-dependent diabetes—offering hope for more effective treatment modalities in the future.

Central to supporting the growth of these cellularized collagen scaffolds is a customized perfusion bioreactor system named VAPOR. This inventive platform establishes a secure connection between the soft tissue scaffolds and the fluidic system, allowing researchers to manipulate and control the environment in which the tissues are cultivated. Remarkably, Shiwarski notes that this bioreactor design permits easy assembly, likening the process to playing with Lego blocks—demonstrating an intuitive and user-friendly approach to complex tissue engineering tasks.

Moreover, unlike conventional microfluidic devices that are limited by their flat configurations, Shiwarski’s team has demonstrated the capacity to create intricate non-planar three-dimensional networks with their soft organic materials. By crafting helical vascular networks inspired by the structure of DNA, the researchers harness the advantages of microfluidics—such as precise control over fluid dynamics—while incorporating the innate advantages of natural biomaterials.

As Shiwarski concludes, the transformative approach taken by his team shapes the future of tissue engineering. By providing cells with an environment that closely mirrors their natural surroundings, it enables them to thrive and execute their intrinsic biological functions. Consequently, the researchers hope to bridge the gap between simplified two-dimensional models and complex animal studies, paving the way for comprehensive examinations into human-specific diseases.

Looking ahead, Shiwarski’s ambition is to exploit this sophisticated bioprinting platform to delve deeper into vascular diseases such as hypertension and fibrosis. These investigations aim to illustrate how such conditions impact tissue development and functionality—a critical step toward advancing our understanding of human health. The ultimate aspiration lies in transcending traditional animal models, instead implementing more accurate human-based systems that will enhance the fidelity of biological research.

Shiwarski also emphasizes the team’s commitment to open science, ensuring that all models and designs from this groundbreaking project are freely accessible to the research community. By encouraging collaboration and innovation across various scientific disciplines, Shiwarski aims to galvanize efforts toward unraveling the complexities of diseases and fostering a new generation of medical solutions to address pressing global health challenges.

Amidst the pioneering studies and innovations, the underlying message of Shiwarski’s research reflects an unfaltering belief in the power of nature and the innate programming of cells. By recreating ideal environments for cellular growth and interaction, the researchers not only advance the field of tissue engineering but also lay the groundwork for future breakthroughs that could transform the landscape of regenerative medicine as we know it. The vision of producing fully functional human organs through 3D bioprinting may no longer remain a distant dream; instead, it draws tantalizingly close to becoming a reality driven by cutting-edge research and resolute scientific inquiry.

In this age of transformative science, it is crucial to remain vigilant in monitoring the implications of such advancements as they emerge. The excitement surrounding Shiwarski’s work reflects not just immediate concerns but also broader questions related to ethics, accessibility, and the future of healthcare in an ever-evolving biotechnological landscape.

Although these scientific achievements signal a bright future for organ fabrication and disease modeling, navigating the complexities of translating such innovations into viable clinical applications requires careful consideration. While the potential to revolutionize patient care exists, the path forward must ensure that scientific integrity, ethical standards, and public trust remain at the forefront of these groundbreaking endeavors.

As researchers like Shiwarski forge new pathways in tissue engineering, anticipating the eventual impact on clinical practice and patient outcomes becomes paramount. The creation of organ-like structures promises to herald an era where patients may benefit from customized therapies and solutions that accurately reflect human biology and biochemistry. With these daring scientific strides and the zeal for discovery, the horizon glows with the promise of pioneering transformations that could shape the future of medicine.

Subject of Research: 3D bioprinting of collagen-based scaffolds
Article Title: 3D bioprinting of collagen-based high-resolution internally perfusable scaffolds for engineering fully biologic tissue systems
News Publication Date: 23-Apr-2025
Web References: Science Advances DOI
References: N/A
Image Credits: Credit: Daniel Shiwarski

Keywords

For the first time, researchers have demonstrated that this gene silencer can effectively prevent the manifestation of ADLD in individuals who possess a genetic mutation related to the condition. Traditionally viewed as the mere byproduct of evolutionary processes, junk DNA is now being recognized for its vital role in gene regulation. The findings indicate that the presence of the silencer can differentiate between individuals who will go on to develop the disease and those who will remain unaffected, despite carrying the same genetic risk factors. This nuance has profound implications for genetic counseling and the assessment of genetic risks in patients with a history of neurodegenerative diseases.

The study’s lead author, Quasar Padiath, M.B.B.S., Ph.D., emphasized the significance of this finding, highlighting how the research offers new hope to patients previously diagnosed with a grim prognosis. Traditionally, genetic counseling around ADLD has focused solely on the presence of the lamin B1 gene duplication, which correlates with the disease. However, this new layer of understanding suggests that not all individuals with this mutation will succumb to the disease due to the protective silencer element. This is particularly important for families navigating the emotional and psychological burdens associated with genetic illnesses.

Padiath’s team pioneered their investigation as a direct result of an unexpected conversation related to the lamin B1 gene. This moment underscores the collaborative nature of scientific research, where chance connections can lead to monumental discoveries. By analyzing various families, some of whom displayed the gene duplication without exhibiting disease symptoms, researchers began to unravel the complexities of gene expression and regulation.

Utilizing advanced genetic techniques, including CRISPR gene editing and computational simulations, the research team identified the specific silencer element within the non-coding regions of the genome. These regions, long dismissed as irrelevant, are now understood to harbor crucial regulatory elements that influence gene activity. In particular, the researchers pinpointed that the silencer acts selectively on the oligodendrocytes, a type of glial cell responsible for forming myelin, effectively modulating the expression of the lamin B1 gene.

The discovery challenges long-held assumptions surrounding the connection between genetic mutations and disease presentation. While the lamin B1 gene duplication is found in numerous individuals, the resultant disease symptoms are confined to a subset of the population. The presence of the gene silencer appears to be a decisive factor in this discrepancy, raising profound questions about how editors within our DNA may shield us from certain genetic illnesses.

The implications of this research extend beyond ADLD, as the findings may hold key insights into a broader spectrum of demyelinating diseases such as multiple sclerosis. As geneticists delve deeper into the functions of non-coding DNA, the potential for uncovering new therapeutic strategies becomes increasingly promising. Unlocking the mysteries of junk DNA may yield groundbreaking insights into a range of genetic disorders, shifting paradigms in genetic research and treatment.

Understanding the roles of structural variants and their interactions with regulatory elements like gene silencers underscores the need for a reassessment of genetic counseling practices. The knowledge that a seemingly controlling mutation can lead to a benign outcome in those carrying it allows for more nuanced discussions between patients and healthcare providers. Genetic counseling can now incorporate testing for silencers, potentially reassuring patients and families burdened by the prospect of hereditary neurological diseases.

As researchers continue to dissect the complexities of gene regulation, the role of genetic counseling in the management of hereditary conditions like ADLD must evolve. The ability to differentiate between patients who may develop symptoms and those who will not based on critical factors like gene silencers represents an invaluable tool in personalized medicine. The findings underscore the importance of integrating cutting-edge research into clinical practice to enhance patient outcomes and quality of life.

The research was supported by several institutions, including the National Institutes of Health, which recognizes the significance of this work in advancing our understanding of genetic diseases. Increased funding and collaborative efforts in the field of genetics are crucial as scientists aim to make sense of the intricate dance between genes, regulation, and expression. The discoveries made by Padiath and his team pave the way for future studies that could usher in an era of targeted therapies and innovative treatment approaches for patients affected by genetic disorders.

As we move forward in understanding these complex genetic interactions, the significance of education and public awareness cannot be overstated. Heightened awareness of genetic risks and the potential for benign outcomes can empower individuals and families dealing with hereditary conditions to seek genetic testing and counseling. In doing so, they may gain valuable insights into their health and the options available to them, leading to informed decisions and proactive measures.

This research serves as a reminder of the uncharted territory that lies in the realm of genetics. The more we explore the subtleties of our DNA, the more we uncover its immense potential and the complex web of interactions at play. With each new discovery, we come closer to a more comprehensive understanding of human health and disease, an endeavor that holds the promise of revolutionary advancements in medical science.

With this understanding, we can anticipate not merely a future of improved diagnostic capabilities, but also the genesis of new therapeutic interventions that could one day change the landscape of medicine as we know it. The insight garnered from the study of gene silencers is but one of many threads in the rich tapestry of genetic research, a narrative that is continuously unfolding as we strive to unravel the intricacies of our biological make-up.

The research reveals that the functions of gene silencers may extend into unexplored areas of human genetics. As advances in techniques and technologies allow scientists to probe deeper into the genome, we can expect further discoveries that challenge our current perceptions and drive innovations in the treatment of various genetic disorders. This journey into the complexity of life at the molecular level may ultimately lead to breakthroughs that enhance our understanding and management of diseases that have long eluded effective treatment.

In conclusion, the study emphasizes the importance of understanding gene regulation and expression in the context of genetic diseases. It may redefine our approach to genetic disorders, not only in terms of diagnosis but also in offering hope to individuals and families grappling with the implications of genetic mutations. As we move forward in this field, the emphasis on collaboration, innovation, and a holistic understanding of genetic factors will be key to unlocking further secrets of the genome.

Subject of Research: Gene silencer in autosomal dominant leukodystrophy
Article Title: An oligodendrocyte silencer element underlies the pathogenic impact of lamin B1 structural variants
News Publication Date: February 5, 2025
Web References: Nature Communications
References: National Institutes of Health funding details can be found in the manuscript.
Image Credits: Joshua Franzos, University of Pittsburgh

Keywords: Gene silencing, Gene regulation, Gene duplication, Regulatory genes, Genetic counseling, Demyelinating diseases, Noncoding DNA, Genetic disorders, Public health, Discovery research.

Historically, much of the focus in Alzheimer’s research has been on amyloid-beta pathology, a hallmark of the disease that often presents in the brain prior to tau protein aggregation. This heightened emphasis on amyloid-beta has overshadowed the significant role that tau tangles play in the disease’s progression. Tau protein abnormalities, particularly neurofibrillary tangles, are proving to be more closely correlated with cognitive impairment than amyloid deposits. Researchers at the University of Pittsburgh have uncovered the potential for early detection of tau tangles, paving the way for timely therapeutic interventions.

Through meticulous biochemical and molecular biology techniques, the study identified a specific core region of the tau protein responsible for the formation of neurofibrillary tangles. This discovery has led to the innovation of a biomarker test capable of detecting clumping-prone tau proteins significantly earlier than conventional imaging methods, which often show tangible signs of tau tangles only after considerable brain damage has occurred. The breakthrough indicates that the biomarkers phospho-tau serine-262 and serine-356 can serve as indicators of early tau aggregation, offering hope for reversing cognitive decline with prompt intervention.

The key finding of this research is its ability to identify neurofibrillary tangles in patients years before noticeable cognitive decline or significant brain pathology can be observed through existing scanning techniques. This is particularly crucial, as it enables healthcare providers to target individuals who may still benefit from Alzheimer’s therapies, thus increasing the chances of effective management of the disease. Thomas Karikari, the senior author of the study, articulates the importance of early detection: through precision diagnostics, it is now possible to determine which patients are more likely to respond favorably to emerging Alzheimer’s therapies.

The implications of this research extend far beyond mere detection; they suggest a paradigm shift in how we assess risk factors for Alzheimer’s disease. Karikari’s team emphasizes that, contrary to prior beliefs, the presence of brain amyloid-beta is not a definitive indicator that an individual will develop cognitive symptoms. Many individuals harbor amyloid deposits without ever progressing to dementia, which underscores the need for comprehensive diagnostic criteria that incorporate tau protein metrics. This approach aligns with the Alzheimer’s Association’s framework, which necessitates the combined assessment of tau, amyloid-beta, and neurodegeneration for a reliable diagnosis of Alzheimer’s disease.

The rigorous nature of this study is underscored by a large collaborative effort involving researchers from the University of Gothenburg, University of Warwick, McGill University, University of California, San Diego, and University College London. The diverse participation of international scholars emphasizes the universal nature of the Alzheimer’s challenge and the collaborative spirit needed to confront it. This collective expertise has enriched the findings, allowing for the development of robust methodologies and analyses that lend credence to the novel biomarker test.

To better inform practice, the identification of tau aggregates through this new method will enable healthcare practitioners to approach Alzheimer’s cases more strategically. By incorporating these early biomarkers into diagnostic protocols, clinicians can prioritize interventions for those at high risk before the disease advances to debilitating stages. This proactive stance in managing Alzheimer’s could transform the lives of countless individuals by delaying or even preventing the onset of severe cognitive impairment.

Additionally, the research opens a dialogue about the capabilities of blood and cerebrospinal fluid testing for tau proteins, reinforcing the need for more accessible and less invasive diagnostic tools. Current practices often rely on expensive imaging techniques or invasive procedures, which may not be suitable for all patients. Consequently, the pursuit of blood-based biomarkers appears promising, as they offer a feasible pathway for widespread screening, particularly in populations at risk for Alzheimer’s.

As the scientific community grapples with the multifaceted nature of Alzheimer’s disease, this research underlines the urgency for early detection mechanisms. The findings resonate not only with medical professionals but also with families affected by the disease, emphasizing that understanding and mitigating risks associated with tau tangles could offer newfound hope. Enhanced awareness about the role of tau proteins may catalyze research funding and initiatives focused on developing personalized treatment approaches based on individual biomarker profiles.

Finally, the implications of this breakthrough extend to public health initiatives aimed at addressing Alzheimer’s disease. Incorporating advanced neurobiological models into community health strategies can facilitate better-informed decisions, benefiting both healthcare systems and patient communities. As the demand for effective Alzheimer’s treatments continues to grow, the research community must remain committed to exploring innovative methods of early detection and intervention.

Overall, this study marks a pivotal moment in Alzheimer’s research, encouraging a reevaluation of existing diagnostic criteria and methodologies. By shifting the focus towards tau protein dynamics, it presents a compelling case for redefining how we understand and confront Alzheimer’s disease. As a society, investing in breakthroughs like this could yield transformative results that lead to improved quality of life for those at risk of developing cognitive decline.

Subject of Research: Early detection of tau tangles in Alzheimer’s disease
Article Title: ‘Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease’
News Publication Date: 10-Feb-2025
Web References: Nature Medicine
References: N/A
Image Credits: UPMC

Keywords: Alzheimer’s disease, biomarkers, tau proteins, neurodegeneration, cognitive decline, blood test, cerebrospinal fluid, early detection.

The study, published in the esteemed journal JAMA Network Open, compares a one-page medication guide proposed by the U.S. Food and Drug Administration (FDA) with a more detailed alternative created by a team of researchers at the University of Pittsburgh. While the FDA’s handout aims to be clear and concise, the researchers argue that it lacks the nuanced information essential for patients to truly grasp both the risks and benefits of their medications.

Lead author Tamar Krishnamurti, Ph.D., a respected associate professor at the Pitt School of Medicine, pointed out that although the FDA’s approach offers simplicity, it fails to communicate the complexities of mifepristone’s associated risks. In her view, the mere presentation of risks assumes that recipients have prior knowledge of the drug’s benefits, which may not always be the case.

In the current regulatory environment, PMIs are distributed in specific scenarios to inform patients about drugs that carry significant risks. However, these handouts often lack a standardized format, leading to lengthy, and at times convoluted, documents. According to Krishnamurti and her collaborators, the existing regulatory measures could be significantly improved to enhance both patient safety and comprehension.

The FDA’s recent proposal for a new standardized one-page PMI aims to simplify the communication of essential drug-related information. It is designed to provide clear instructions for usage, safety warnings, and potential side effects. However, critics argue that what is still lacking in this approach is a requirement to quantify the benefits of the medications or clearly outline how effective they truly are.

Krishnamurti pointed out that there might be a prevailing assumption at the FDA that healthcare providers will adequately convey the benefits of medications during consultations with patients. However, she asserts that PMIs should be self-sufficient documents capable of conveying all critical information needed for patients to make informed decisions. Additionally, she highlights the importance of communicating the probability of risks and benefits, advocating that patients deserve to know not only if an outcome is possible but also its likelihood.

As part of the study, the research team created what they termed a Decision Critical PMI, enhancing the FDA’s proposed materials with essential content that explains how mifepristone works, its success rates, and how common side effects might manifest. For instance, instead of vague statements about side effects like fever or headaches, the Decision Critical PMI provides specific statistics about how often these side effects occur. This granular approach to information-sharing could help improve patients’ understanding and decision-making processes.

To evaluate the efficacy of different PMIs, the researchers conducted an online survey involving 330 female participants. Each participant was randomly assigned one of three varying PMIs: the vendor’s five-page guide, the FDA’s one-page PMI, or the newly crafted Decision Critical PMI. Following their review of the materials, participants were assessed on their comprehension and the perceived usefulness of the handed-out information.

The results were compelling. Both the FDA’s PMI and the Decision Critical PMI were noted to exhibit higher readability when compared to the vendor’s lengthy guide. Moreover, the Decision Critical PMI significantly outperformed the other two formats in terms of facilitating comprehension, aiding in decision-making, and providing clear usage directions. This evidence supports the argument that transparency in communicating risk is vital for helping patients navigate their healthcare choices.

Krishnamurti emphasizes the necessity for transparency in medical communications, advocating for a practice where healthcare professionals empower patients to understand the implications of their medications fully. The findings align with a growing body of evidence that points to a shift in how patient information should be structured, compelling regulators like the FDA to reconsider their current guidelines for PMIs.

Interestingly, while the FDA’s proposal outlines the necessary topics to cover in PMIs, there is presently no stipulation for pharmaceutical companies to validate the effectiveness of their messaging through user testing—in other words, no requirement to assess how well patients understand their PMIs. Krishnamurti advocates for a policy shift that necessitates such testing, asserting that if the goal is to enhance patient understanding and safety, user comprehension should be a priority in the regulatory framework.

The implications of these findings are far-reaching, particularly in today’s environment, where misinformation can rapidly circulate, especially regarding medications like mifepristone that are often subject to public debate and confusion. Clear and accurate PMIs are not just beneficial but vital for equipping patients with the knowledge they require to navigate their medical options confidently.

In conclusion, the ongoing discourse surrounding medication information emphasizes the critical need for effective communication strategies in healthcare. As this research demonstrates, the way we present information can significantly influence patient comprehension and decision-making. With the potential for changes on the horizon regarding FDA regulations, there is hope for a future where patient medication information is standardized, accurate, and ultimately bolstered by user testing to ensure clarity and understanding.

Subject of Research: Effectiveness of patient medication information handouts
Article Title: Public Understanding of Risk and Benefit of Mifepristone
News Publication Date: 6-Feb-2025
Web References: JAMA Network
References: None available
Image Credits: None available

Keywords: Patient medication information, mifepristone, FDA guidelines, drug risks, patient safety, healthcare communication, informed decision-making